Glioblastoma Multiforme (GBM)
22
10
12
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
4.5%
1 terminated out of 22 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (22)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NK Cell Therapy for Malignant Solid Brain Tumors
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
5G-PEARL: Paxalisib in Malignant Brain Tumours
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Allogeneic γδT Cells in Glioblastoma
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Patient's Derived Organoids for Drug Screening in Glioblastoma
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients